Experimental surgical robot performs gallbladder procedure autonomously
gallbladder operation
, marking a major step toward automated medical procedures, researchers said on Wednesday.
Existing surgical robots are remotely controlled by surgeons. The new system uses artificial intelligence to make independent decisions and adapts to unexpected complications during operations, said Axel Krieger of
Johns Hopkins University
in Baltimore, who led the research.
He likened it to an autonomous vehicle that can "navigate any road, in any condition, responding intelligently to whatever it encounters."
"This advancement moves us from robots that can execute specific surgical tasks to ones that truly understand surgical procedures," he said.
The
SRT-H robot
was trained via an AI framework known as language-guided imitation learning, using videos of surgeons performing gallbladder removal surgeries on pig cadavers, the researchers reported in Science Robotics.
The robot was tested on eight varying sets of pig gallbladders and livers that had been removed from the animals.
Separating the gallbladder from the liver takes several minutes and involves "diverse tool use, including grabbing, clipping, and cutting - skills common in real surgical procedures," along with decision-making and adaptation, the researchers said.
The pig organs and blood vessels in the tests varied widely in appearance and anatomy, "mirroring the diversity encountered in human surgeries," they said.
While the robot achieved 100% accuracy in the surgeries, it took longer to perform the work than a human surgeon.
Commercially available surgical robots include Intuitive Surgical's da Vinci Surgical System, which has been used in over 12 million procedures globally since receiving FDA approval in 2000.
Unlike SRT-H, the da Vinci system relies entirely on human surgeons to control its movements remotely.
The global surgical robotics market is approaching $10 billion annually with about 2.7 million robotic procedures performed in 2024, Baird analyst David Rescott estimated.
Eventually, autonomous surgical robots could help address surgeon shortages, minimize human error, and provide consistent, high-quality care in underserved regions, the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
NASA's Parker Probe Captures Closest-Ever Image Of The Sun
Last Updated: NASA's Parker Probe captured the first-ever images from inside a solar eruption, offering vital clues about space weather and its effects on Earth The Sun, Earth's most powerful energy source, has long been a subject of awe and concern due to its sheer scale and volatile nature. Now, NASA's Parker Solar Probe has delivered astonishing new images that provide a close-up look inside the Sun's atmosphere; images as mesmerising as they are menacing. Closest Flyby Reveals Intense Solar Activity On December 24, 2024, the Parker Solar Probe made its closest-ever approach to the Sun, reaching just 3.8 million miles from its surface. During this moment, the onboard WISPR camera (Wide-field Imager for Parker Solar Probe) captured a live eruption of a Coronal Mass Ejection (CME). This marks the first time scientists have directly recorded such a violent solar event from within, rather than simulating it through models. Deadly Solar Waves Observed First-Hand Within the CME, scientists observed Kelvin-Helmholtz Instabilities—swirling, wave-like patterns formed by the collision of solar flows. Once considered purely theoretical or seen only in simulations, these dangerous waveforms have now been witnessed in real solar conditions. Unprecedented Footage From Inside the Corona NASA released a video showing the Sun's corona from the probe's perspective. According to Angelos Vourlidas from Johns Hopkins University, USA, the footage shows CMEs colliding and merging, giving researchers insight into how space weather forms and evolves. NASA's Dr Nicky Fox added, 'We are finally seeing where Earth's space weather begins". Against All Odds: The Probe Survives Extreme Heat Despite temperatures above 1,300°C and intense radiation, the Parker Probe emerged undamaged. NASA engineers regard this survival as a historic feat in space engineering. What's Next For Parker? The probe's next flyby is set for September 15, 2025, where it will venture even closer to the Sun. Scientists are optimistic that this mission will help decode the origin of solar winds, which are critical in understanding and forecasting space weather. Why This Matters For Earth Space weather caused by CMEs can disrupt satellites, GPS systems, radio signals, and even power grids on Earth. These new findings will help scientists build better early-warning systems, protecting both astronauts and everyday technologies on Earth. view comments First Published: July 12, 2025, 14:06 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
3 hours ago
- Hans India
New weekly injection to offer steady Parkinson's medication, cut need for daily pills
A team of scientists in Australia, led by those of Indian origin, has developed a new once-a-week injectable drug that could transform the lives of more than eight million people living with Parkinson's disease, potentially replacing the need for multiple daily tablets. Frequent dosing is a burden, especially for elderly patients or those with swallowing difficulties, leading to inconsistent medication levels, more side effects, and reduced effectiveness. To address this, the team from the University of South Australia (UniSA) developed a long-acting injectable formulation that delivers a steady dose of levodopa and carbidopa -- two key medications for Parkinson's -- over an entire week. The biodegradable formulation is injected under the skin or into muscle tissue, where it gradually releases the medication over seven days, noted the researchers in the paper published in the journal Drug Delivery and Translational Research. The newly developed injectable could significantly improve treatment outcomes and patient adherence, said lead researcher Professor Sanjay Garg, from UniSA's Center for Pharmaceutical Innovation. "Our goal was to create a formulation that simplifies treatment, improves patient compliance, and maintains consistent therapeutic levels of medication. This weekly injection could be a game-changer for Parkinson's care," Garg said. "Levodopa is the gold-standard therapy for Parkinson's, but its short lifespan means it must be taken several times a day." The injectable gel combines a US FDA-approved biodegradable polymer, PLGA, with Eudragit L-100, a pH-sensitive polymer, to achieve a controlled and sustained drug release. The team noted that the release of both levodopa and carbidopa steadily over a week could help maintain consistent plasma levels and reduce the risks associated with fluctuating drug concentrations. Extensive lab tests confirmed the system's effectiveness and safety. More than 90 per cent of the levodopa dose and more than 81 per cent of the carbidopa dose were released over seven days. Notably, the implant degraded by over 80 per cent within a week and showed no significant toxicity in cell viability tests. In addition, the formulation can be easily administered through a fine 22-gauge needle, minimising discomfort and eliminating the need for surgical implantation. Garg said the technology could also be adapted for other chronic conditions such as cancer, diabetes, neurodegenerative disorders, pain management, and chronic infections that require long-term drug delivery.
Mint
20 hours ago
- Mint
FDA Offers to Trade Faster Drug Reviews for Lower US Prices
Food and Drug Administration Commissioner Marty Makary said his agency may fast-track new drugs from pharmaceutical companies that 'equalize' the cost of their medicines between the US and other countries, an unusual proposition from the regulator that's long avoided contentious pricing debates. The comments, made in an interview on Bloomberg Television's Wall Street Week with David Westin, offer insight into an idea floated to help the administration achieve one of President Donald Trump's main health-care goals: ensuring foreign countries aren't getting a better deal on drugs. Trump demanded that Americans get similar or lower prices as consumers in other countries in an executive order signed in May. Price adjustments may give companies another way to obtain 'national priority vouchers,' the reward that comes as part of a new program the FDA announced last month that would slash review times for companies it says are backing national interests. Makary didn't offer details about how drugmakers would have to adjust their prices to qualify for a voucher. 'We can issue a national priority review voucher for companies that are promising to equalize the price' between the US and what other foreign countries pay, Makary said. 'We want to incentivize good behavior in the marketplace, and these priority vouchers are worth a lot of money.' The new vouchers would cut review times to one to two months, down from an average of about 10 months to one year now, the agency said. In the interview, Makary said the program could be used as a tool to even out drug prices with those currently charged in places like Europe. The Department of Health and Human Services has asked drugmakers to price therapies that don't have generic competition at the lowest level offered to any member country in the Organization for Economic Cooperation and Development that has an economy at least 60% of the size of the US on a per capita basis. The FDA typically has avoided inserting itself into the murky world of drug pricing in the US. Explicitly trading faster reviews for price changes on existing treatments would be abnormal for the agency, which doesn't have authority 'to investigate or control the prices charged for marketed drugs.' It's also unclear how much of an impact the vouchers would have. Makary touted the value of pediatric priority review vouchers offered under a different program, which is currently coming to an end. He noted that some have sold for more than $100 million in a secondary market, which was legal. The new national priority vouchers can't be sold. Drugmakers also have limited control over what patients ultimately pay in the US, where a complex system of insurance companies and drug benefit managers typically operates in the space between where a patient is given a prescription and where they get their medicine from a pharmacy. Still, the approach could offer a financial incentive for drugmakers to lower drug prices. When Trump pursued equalizing costs in the US with those abroad during his first term, he exclusively used a more punitive approach, issuing regulations that would have reduced what Medicare, the health insurance program for the elderly and disabled, pays for medications administered in physicians' offices. In the initial announcement of the voucher program, FDA said they could be offered to return drug manufacturing to the US, address health crises or unmet public health needs, or provide innovative cures. The interview will air Friday at 6 p.m. in New York.
